摘要
目的:为临床医师全面了解奈西立肽的药理学特性,促进该药在临床更好的应用。方法:综合近几年来国内、外文献,综述奈西立肽药理学特性及其临床应用新动向。结果:奈西立肽对于失代偿期心衰的治疗,特别是在急性心肌梗死并发心力衰竭、心力衰竭伴肾衰竭、心力衰竭伴肺动脉高压症时的应用,取得满意的疗效。结论:奈西立肽是治疗心力衰竭的一线药物,研究进展较快,有很好的应用前景。
OBJECTIVE： To facilitate clinicians＇ thorough understanding of the pharmacological characteristics of rhBNP （Lyophilnzed Recombinant Human Brain Natriuretic Peptide） and promote its clinical application. METHODS： The pharmacological characteristics and new clinical application of nesiritide were reviewed through a meta- analysis of domestic and foreign documents about this medicine. RESULTS： Nesiritide has satisfying effects in treating decompensated heart failure, especially for acute myocardial infarction accompanied by heart failure, heart failure accompanied by renal failure, and heart failure accompanied by pulmonary hypertension. CONCLUSION： Nesiritide is the first line therapy for heart failure. The research on Nesiritide has achieved a rapid progress and its clinical application hold an optimistic outlook.
出处
《中国医院用药评价与分析》
2010年第6期491-493,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
